

# 東邦大学学術リポジトリ



## OPAC

東邦大学メディアセンター

タイトル	Changes in the blood flow of the optic nerve head induced by different concentrations of epinephrine in intravitreal infusion during vitreous surgery
別タイトル	硝子体手術中のエピネフリン眼内灌流によって惹起される視神経乳頭血流の変化
作成者（著者）	産賀, 真
公開者	東邦大学
発行日	2015.02
掲載情報	東邦大学大学院医学研究科 博士論文. 4.
資料種別	学位論文
内容記述	主査：富田剛司 / タイトル：Changes in the blood flow of the optic nerve head induced by different concentrations of epinephrine in intravitreal infusion during vitreous surgery / 著者：Makoto Ubuka, Tetsuya Sugiyama, Yasutaka Onoda, Tomoaki Shiba, Yuichi Hori, Takatoshi Maeno / 掲載誌：Investigative Ophthalmology & Visual Science / 巻号・発行年等：55(3):1625-1629, 2014 / 本文ファイル：査読後原稿 /
著者版フラグ	ETD
報告番号	32661乙第2827号
学位授与年月日	2015.02.24
学位授与機関	東邦大学
DOI	info:doi/10.1167/iops.13-13801
その他資源識別子	<a href="http://iovs.arvojournals.org/article.aspx?articleid=2190166">http://iovs.arvojournals.org/article.aspx?articleid=2190166</a>
メタデータのURL	<a href="https://mylibrary.toho-u.ac.jp/webopac/TD52811910">https://mylibrary.toho-u.ac.jp/webopac/TD52811910</a>

1 **Changes in the Blood Flow of the Optic Nerve Head Induced by Different**  
2 **Concentrations of Epinephrine in Intravitreal Infusion During Vitreous Surgery**

3  
4 Makoto Ubuka<sup>1</sup>, Tetsuya Sugiyama<sup>2</sup>, Yasutaka Onoda<sup>1</sup>, Tomoaki Shiba<sup>1</sup>, Yuichi Hori<sup>1</sup>,  
5 Takatoshi Maeno<sup>1</sup>

6  
7 <sup>1</sup>Department of Ophthalmology, Toho University Sakura Medical Center, 564-1,  
8 Shimoshizu, Sakura, Chiba 285-8741, Japan

9 <sup>2</sup>Nakano Eye Clinic of Kyoto Medical Co-operative, 2, Jurakukaitou-cho, Nakagyo-ku,  
10 Kyoto 604-8404, Japan

11  
12 **Corresponding Author:** Tetsuya Sugiyama, M.D., Ph.D., Nakano Eye Clinic of Kyoto  
13 Medical Co-operative, 2, Jurakukaitou-cho, Nakagyo-ku, Kyoto 604-8404, Japan  
14 Telephone: +81-75-801-4151; Fax: +81-75-822-7423  
15 E-mail: [tsugiyama@poh.osaka-med.ac.jp](mailto:tsugiyama@poh.osaka-med.ac.jp)

16  
17 **Word Count:** Abstract: 217; main text (excluding the title page, legends, and  
18 references, but including the abstract): 2,512

19 **Financial Disclosure:** None

20 **Funding/Support:** None

25 **ABSTRACT**

26 **Purpose:** To investigate whether intravitreal infusion solution containing epinephrine  
27 affects optic nerve head (ONH) blood flow during vitreous surgeries.

28 **Methods:** The subjects were 22 patients with epimacular membrane or idiopathic  
29 macular hole. During vitreous surgery, ONH blood flow was examined before and 10  
30 min after intravitreal infusion of solution containing epinephrine, via a laser speckle  
31 flowgraphy (LSFG) technique modified for acquiring measurements in a supine  
32 position. Epinephrine concentration was set at 1.0 mg/500 ml (1:500,000) or 0.5 mg/500  
33 ml (1:1,000,000), with each concentration assigned to 11 consecutive patients. Relative  
34 pupil diameter, intraocular pressure (IOP), blood pressure, and pulse rate were also  
35 measured.

36 **Results:** A significant reduction in blood flow throughout the ONH was induced by  
37 intravitreal infusion of epinephrine at 1:500,000, but not at 1:1,000,000. Blood flow in  
38 ONH tissue was diminished at both concentrations, while that in vessels of the ONH  
39 was not altered significantly by either concentration. Both epinephrine concentrations  
40 induced significant pupillary dilatation, but no significant changes in IOP, blood  
41 pressure, or pulse rate.

42 **Conclusions:** This study suggests that epinephrine, used in combination with  
43 intravitreal infusion solution, may decrease ONH blood flow during vitreous surgeries,  
44 as indicated by measurements obtained via a modified LSF technique. Attention must  
45 be paid to the effects of intravitreal infusion of epinephrine on ocular circulation,  
46 particularly ONH blood flow.

47

48 **Key words:** Epinephrine, optic nerve head, blood flow, laser speckle flowgraphy,  
49 vitreous surgery, supine position

50 **INTRODUCTION**

51 Intraocular irrigating solution containing epinephrine is usually used to maintain  
52 mydriasis of the eye being operated on during vitreous surgery.<sup>1</sup> There have been  
53 several reports<sup>2-8</sup> regarding the effect of epinephrine or its prodrug, dipivefrine, on  
54 ocular blood flow. Some have reported that no effect on retinal, choroidal, or optic nerve  
55 head (ONH) blood flow was observed after a single application of epinephrine (1–4%)  
56 eye drops in phakic eyes of monkeys or rabbits,<sup>2,4,5</sup> while significant alterations in blood  
57 flow at those locations were reportedly induced in aphakic eyes.<sup>3,4,5</sup> Others have  
58 reported that neither a single retrobulbar epinephrine (0.2%) injection nor multiple  
59 applications of epinephrine (2%) over 5–6 weeks altered posterior ocular blood flow in  
60 rabbits.<sup>6,7</sup> In addition, a single administration of dipivefrine, a prodrug of epinephrine,  
61 reportedly yielded no significant change in tissue circulation in human ONH.<sup>8</sup> It has  
62 also been reported that supplementing epinephrine (1:200,000) to retrobulbar anesthesia  
63 reduced blood velocities in the ophthalmic, central retinal, and posterior ciliary arteries  
64 of the eyes of primates, and humans during cataract surgeries.<sup>9,10</sup> To the best of our  
65 knowledge however, to date there have been no reports on the effects of epinephrine  
66 added to intravitreal infusion solution on human ONH blood flow during surgery.

67 Laser speckle flowgraphy (LSFG) is an imaging technique that can analyze the blood

68 flow of the retina, choroid, and ONH quantitatively and non-invasively.<sup>11,12</sup> With regard  
69 to the medical equipment used to perform it, LSF<sub>G</sub>-NAVI™ (Softcare Ltd., Iizuka,  
70 Japan)<sup>13-17</sup> is currently used in Japan, and is commercially available. The LSF<sub>G</sub>  
71 equipment was improved in order to measure the ocular blood flow of patients in a  
72 supine position during surgery, although there is a report on the measurement of the  
73 ONH blood flow of subjects in a supine position which is unrelated to surgery.<sup>17</sup>

74 In the current study, we investigated whether epinephrine, used in combination with  
75 intravitreal infusion solution, affects ONH blood flow during vitreous surgery, via  
76 measurements obtained by LSF<sub>G</sub>.

77

## 78 **METHODS**

### 79 *Subjects*

80 Twenty-two eyes of 22 patients (15 with epimacular membrane and 7 with idiopathic  
81 macular hole; mean age  $70.3 \pm 7.2$  years; 6 males, 16 females) who underwent vitreous  
82 surgery in Sakura Medical Center of Toho University were included in the study. All  
83 procedures were in full compliance with the guidelines of the Declaration of Helsinki,  
84 and were approved by the Institutional Review Board/Ethics Committee of Toho  
85 University. All participants provided informed consent to participate, and the nature and

86 possible consequences of the study were explained to them prior to the provision of this  
87 consent. Patients with glaucoma, atrial fibrillation, or uncontrolled hypertension were  
88 excluded from the study, as were patients on hemodialysis.

89 ***Experimental Protocol***

90 All patients underwent micro-incision vitreous surgery with a 23-gauge instrument  
91 using the Accurus<sup>®</sup> (Alcon, Fort Worth, TX) vented gas forced infusion (VGFI) system,  
92 under topical anesthesia with retrobulbar injection of 2% lidocaine hydrochloride  
93 (Xylocaine, AstraZeneca, Osaka, 2.5 ml) and 0.75% ropivacaine hydrochloride  
94 (Anapaine, AstraZeneca, 2.5 ml). Patients were instructed to refrain from eating,  
95 smoking, and drinking coffee or alcohol for a minimum of 3 hours prior to the surgery.  
96 Mydriasis was induced by the administration of eye drops containing 0.5% tropicamide  
97 and 0.5% phenylephrine hydrochloride (Mydrin<sup>®</sup>-P ophthalmic solution, Santen  
98 Pharmaceutical Co. Ltd., Osaka, Japan), 7 times at 30 min intervals prior to the surgery.  
99 After performing core vitrectomy and posterior vitreous detachment under infusion of  
100 an epinephrine-free BSS PLUS<sup>®</sup> 500 intraocular irrigating solution (Santen  
101 Pharmaceutical Co. Ltd.), the ONH blood flow of patients in a supine position was  
102 measured 3 times by LSFG under a stabilized infusion pressure of 10 mmHg using the  
103 VGFI system; the IOP was kept almost constant by ensuring that the distance between

104 the bottle containing the irrigating solution and the patient's eye remained constant. Ten  
105 minutes after 50 ml of epinephrine (1 mg or 0.5 mg)-containing BSS PLUS<sup>®</sup>500  
106 intraocular irrigating solution (500 ml) was infused at 10 mmHg, ONH blood flow was  
107 measured again using the same method. One milligram and 0.5 mg of epinephrine were  
108 each assigned to 11 consecutive patients. The characteristics of each group are shown in  
109 Table 1. As shown in this table, some of the patients also underwent  
110 phacoemulsification cataract surgery before vitreous surgery. Cataract surgery was  
111 performed under infusion of an epinephrine-free BSS PLUS<sup>®</sup>500 intraocular irrigating  
112 solution. None of the parameters in Table 1 differed significantly between the groups.

113 ***Measurement of ONH Blood Flow***

114 The principle and method of ONH blood flow determination using LSFG were  
115 described previously.<sup>11,12</sup> In the current study, the mean blur rate (MBR), an indicator of  
116 blood flow,<sup>13</sup> was obtained by LSFG-NAVI-OPE<sup>™</sup> (Softcare Ltd.), a modified type of  
117 LSFG-NAVI<sup>™</sup>. LSFG-NAVI-OPE<sup>™</sup> was recently developed for ocular blood flow  
118 measurement in subjects in a supine position. Schemata and photos of this device are  
119 shown in Supplementary Figure S1. The camera equipped in LSFG-NAVI-OPE<sup>™</sup> is set  
120 on tilting stages with two axes ( $\varphi$  and  $\theta$ ), and X-Y stages to adjust the field of view and  
121 to ensure the required alignment of the camera with the subject's eye. These stages are



122 held by a long adjustable mechanical arm, facilitating their placement above the  
123 subject's face.

124 Three parameters of the MBR in the ONH were calculated using LSFG Analyzer  
125 software (v 3.0.47; Softcare Ltd.). After we had identified the margin of the ONH by  
126 hand using a round band, the software separated out the vessels using the automated  
127 definitive threshold, and analyzed the mean of the MBRs throughout the ONH  
128 (MBR-A), in vessels of the ONH (MBR-V), and in the ONH tissue (MBR-T).<sup>13</sup>

#### 129 *Analysis of the Reproducibility of ONH Blood Flow Measurements*

130 As an index of reproducibility, a coefficient of variance defined as  $100 \times (\text{SD}/\text{mean}) (\%)$   
131 was calculated from values derived from three continuous measurements of MBR for  
132 each case, then the mean  $\pm$  SD at each time-point (pre-treatment and post-treatment)  
133 was calculated for each group.

#### 134 *Measurement of Pupil Diameter, Intraocular Pressure, Blood Pressure, and Pulse*

##### 135 *Rate*

136 Relative pupil diameter (pupil diameter/corneal diameter, relative PD), intraocular  
137 pressure (IOP), blood pressure, and pulse rate were also measured at the same time that  
138 ONH blood flow was measured. Pupil and corneal diameters were obtained from  
139 images recorded by a digital video recorder (D-VDR9K, TOSHIBA, Tokyo, Japan)

140 during the surgery. Changes in relative PD were calculated by the following equation:  
141  $100 \cdot (\text{post-treatment relative PD} - \text{pre-treatment relative PD}) / \text{pre-treatment relative PD}$   
142 (%). Tonopen-AVIA<sup>®</sup> (Reichert Inc., Buffalo, NY) was used to measure IOP. Blood  
143 pressure and pulse rate were measured with a bedside monitor (BSM-5132,  
144 Nihon-Kohden, Tokyo, Japan). Ocular perfusion pressure (OPP) was then calculated as  
145 two-thirds of mean blood pressure minus IOP.

#### 146 *Statistical Analyses*

147 Data are expressed as mean  $\pm$  standard deviation (SD) or mean  $\pm$  standard error of the  
148 mean (SEM). Statistical analyses were performed using paired and unpaired *t*-tests, or  
149 Fisher's exact test. Differences were deemed to be statistically significant if  $p < 0.05$ .

150

## 151 **RESULTS**

152 With regard to reproducibility, the coefficients of variance (%) of MBR-A, MBR-V, and  
153 MBR-T ranged from 3.1–5.8, 5.7–6.9, and 3.8–6.5 respectively, as shown in Table 2.

154 Their averages were (%) 4.1, 6.2, and 5.6 respectively.

155 Figure 1 shows representative MBR measurements before and after treatment with  
156 epinephrine in two patients; each patient received both concentrations of epinephrine.

157 MBR-A decreased significantly after infusion with solution containing 1.0 mg/500 ml

158 of epinephrine, but not after infusion with solution containing 0.5 mg/500 ml of  
159 epinephrine (Table 3). The mean reduction rates (%) for the 1.0 mg/500 ml and 0.5  
160 mg/500 ml concentrations were 9.75 and 4.28 respectively. MBR-T was diminished at  
161 both concentrations, while MBR-V was not altered significantly at either concentration  
162 (Table 3). The mean reductions (%) in MBR-T for 1.0 mg/500 ml and 0.5 mg/500 ml  
163 were 12.2 and 11.8 respectively.

164 Relative PD was significantly increased, whereas IOP, blood pressure, OPP and pulse  
165 rate did not change significantly after the infusion of epinephrine at either concentration  
166 (Table 4). There was no significant difference between the infusion of 0.5 mg/500 ml of  
167 epinephrine and 1.0 mg/500 ml of epinephrine, with regard to the changes (%) in  
168 relative PD (mean  $\pm$  SD:  $9.0 \pm 7.6$  and  $9.5 \pm 10.6$  respectively).

169

## 170 **DISCUSSION**

171 The present study indicated that a significant reduction in overall ONH blood flow  
172 (MBR-A) was induced by intravitreal infusion of epinephrine at a concentration of 1.0  
173 mg/500 ml, but not at 0.5 mg/500 ml. However, no statistically significant differences  
174 were apparent between these concentrations with regard to relative PD, IOP, blood  
175 pressure, or pulse rate. Taken together, these results suggest that infusion of epinephrine

176 at 0.5 mg/500 ml is evidently sufficient for maintaining mydriasis during vitreous  
177 surgery.

178 Notably, MBR-T was diminished statistically significantly at both concentrations  
179 tested, but MBR-V was not. It has been reported that in a previous study, retinal arteries  
180 contracted to a significantly greater extent when adrenergic agonists including  
181 epinephrine were applied to the intraluminal surface, rather than to the extraluminal  
182 surface.<sup>18</sup> This suggests that retinal vessels may be resistant to the effects of epinephrine,  
183 to some degree. On the other hand, tissue blood flow in the ONH may respond  
184 differently to blood flow in the ONH vessels, because the ONH tissue blood supply is  
185 derived from capillaries. This may explain the different results for MBR-V and MBR-T  
186 observed in our study.

187 It has previously been reported that epinephrine at 1:200,000 significantly reduced  
188 blood velocities in retrobulbar arteries, including the ophthalmic, central retinal, and  
189 posterior ciliary arteries.<sup>9,10</sup> In the current study, the applied concentration of  
190 epinephrine was 1:1,000,000 in the case of 0.5 mg/500 ml, 5 times less than was used in  
191 those studies.<sup>9,10</sup> The effects of epinephrine on the ocular vessels might therefore have  
192 been weaker in our study. Regardless, it is important to consider the effect of intravitreal  
193 infusion of epinephrine on ocular circulation, particularly with regard to tissue

194 circulation of the ONH, during surgery.

195 In the current study, we measured ONH blood flow in a supine position during  
196 surgery. For that purpose, we used the recently developed LSF<sub>G</sub>-NAVI-OPE™,  
197 modification of the LSF<sub>G</sub>-NAVI-MRC™ that was specifically changed with regard to  
198 parts of the mechanical arm of the device, as described above in the Methods section.  
199 Since this is the first report on the measurement of ocular blood flow using this  
200 modified device, the reproducibility of the measurement was examined. The coefficient  
201 of variance (%) for the measurement of MBR-A in this study (4.1) were comparable  
202 with that obtained by LSF<sub>G</sub>-NAVI in the previous study<sup>13</sup> (3.4). Our results suggest that  
203 the reproducibility of this device is sufficient for measuring ONH blood flow in a supine  
204 position during surgery. Therefore, this device could also be useful for obtaining  
205 measurements from patients who cannot stand up, or examination of changes that occur  
206 when going from a sitting position to a supine position, or the reverse.

207 In the present study, there was significant pupillary dilatation but no significant  
208 changes in IOP, blood pressure, OPP, or pulse rate after intravitreal infusion of  
209 epinephrine. The observation of significant pupillary dilatation caused by topical  
210 epinephrine is concordant with previous reports.<sup>19,20</sup> It has been reported that topically  
211 applied epinephrine induced a significant reduction in IOP in some patients, but not in

212 the others,<sup>21</sup> and rather that it had a biphasic effect on IOP.<sup>19,22,23</sup> With regard to the  
213 effects of topical epinephrine on blood pressure and pulse rate, there is a report that  
214 these did not change significantly after administration of 2% epinephrine.<sup>24</sup> In the  
215 current study, IOP was kept almost constant at approximately 13 to 14 mmHg, which  
216 was within the regulatory range of pressure-flow autoregulation.<sup>25,26</sup> In addition, OPP  
217 was not altered significantly, suggesting that ocular hemodynamic conditions were  
218 maintained constant during the study procedures.

219       Regarding the pharmacokinetics of epinephrine, since some of the patients underwent  
220 cataract surgery before vitreous surgery, the presence of a lens or intraocular lens might  
221 have induced differences. However, because the percentage of cases involving  
222 combined cataract surgery was not significantly different between the two groups, the  
223 difference in pharmacokinetics should affect the results similarly in each group.

224       The current study had several limitations. The thresholds of dose-dependency were  
225 not thoroughly examined, since we only assessed two epinephrine concentrations.  
226 Whether a reduction in ONH blood flow of approximately 10% has an irreversible  
227 impact on the function of the eye (including the ONH) may depend on the duration of  
228 that reduction. However, in the current study the duration of the reduction was not  
229 known, because we only measured ONH blood flow at one time point (10 min). Taking

230 measurements at later time-points was not ethically feasible, because the data for the  
231 study were acquired during surgeries. In addition, the present study was performed  
232 without a placebo control group because of a similar reason (ethical issues). Instead, we  
233 adopted the data under stable conditions and averaged them; we also assigned one of the  
234 groups to a low concentration of epinephrine, which was 5 times less than the  
235 concentration used in the previous reports.

236 A power analysis (Means: difference between two dependent means) by G\* Power  
237 software (v.3.1.3) showed that a total sample size of 32 is needed for an effect size of  
238 0.45 (calculated from the MBR-A values), error probability ( $\alpha$ ) of 0.05 and power (1- $\beta$ )  
239 of 0.8. Therefore, the total sample size of 22 in the current study would be smaller than  
240 the ideal sample size. However, since the practical number of patients that could be  
241 enrolled from one institution over a certain period for such a study would be  
242 approximately 20, the sample size of 22 might be acceptable for an exploratory study.

243 In conclusion, the present study suggests that epinephrine decreases ONH blood flow  
244 during vitreous surgery when used in combination with intravitreal infusion solution, as  
245 indicated by measurements obtained via an LSFSG technique modified for assessing  
246 subjects in a supine position.

247

248 **REFERENCES**

- 249 1. Gimbel HV. The effect of treatment with topical nonsteroidal anti-inflammatory  
250 drugs with and without intraoperative epinephrine on the maintenance of  
251 mydriasis during cataract surgery. *Ophthalmology* 1989;96:585–588.
- 252 2. Alm A. The effect of topical l-epinephrine on regional ocular blood flow in  
253 monkeys. *Invest Ophthalmol Vis Sci.* 1980;19:487–491.
- 254 3. Morgan TR, Mirate DJ, Bowman K, Green K. Topical epinephrine and regional  
255 ocular blood flow in aphakic eyes of rabbits. *Arch Ophthalmol.*  
256 1983;101:112–116.
- 257 4. Caprioli J, Sears M, Mead A. Ocular blood flow in phakic and aphakic monkey  
258 eyes. *Exp Eye Res.* 1984;39:1–7.
- 259 5. Jay WM, Aziz MZ, Green K. Effect of topical epinephrine and timolol on ocular  
260 and optic nerve blood flow in phakic and aphakic rabbit eyes. *Curr Eye Res.*  
261 1984;3:1199–1202.
- 262 6. Jay WM, Aziz MZ, Green K. The effect of retrobulbar epinephrine injection on  
263 ocular and optic nerve blood flow. *Curr Eye Res.* 1985;4:55–58.
- 264 7. Green K, Hatchett TL. Regional ocular blood flow after chronic topical  
265 glaucoma drug treatment. *Acta Ophthalmol (Copenh).* 1987;65:503–506.
- 266 8. Tamaki Y, Tomita K, Araie M, Tomidokoro A, Nagahara M. Effect of topical  
267 adrenergic agents on tissue circulation in human optic nerve head evaluated with  
268 a laser speckle microcirculation analyser. *Nihon Ganka Gakkai Zasshi.*  
269 1996;100:55–62. [Japanese]



- 270 9. Netland PA, Siegner SW, Harris A. Color Doppler ultrasound measurements  
271 after topical and retrobulbar epinephrine in primate eyes. *Invest Ophthalmol Vis*  
272 *Sci.* 1997;38:2655–2661.
- 273 10. Huber KK, Remky A. Colour Doppler imaging before and after retrobulbar  
274 anaesthesia in patients undergoing cataract surgery. *Graefes Arch Clin Exp*  
275 *Ophthalmol.* 2005;243:1141–1146.
- 276 11. Tamaki Y, Araie M, Kawamoto E, Eguchi S, Fujii H. Non-contact,  
277 two-dimensional measurement of tissue circulation in choroid and optic nerve  
278 head using laser speckle phenomenon. *Exp Eye Res.* 1995;60:373–383.
- 279 12. Sugiyama T, Araie M, Rive CE, Schmetterer L, Orgul S. Use of laser speckle  
280 flowgraphy in ocular blood flow research. *Acta Ophthalmol.* 2010;88:723–729.
- 281 13. Aizawa N, Yokoyama Y, Chiba N, et al. Reproducibility of retinal circulation  
282 measurements obtained using laser speckle flowgraphy-NAVI in patients with  
283 glaucoma. *Clin Ophthalmol.* 2011;5:1171–1176.
- 284 14. Shiba T, Takahashi M, Hori Y, Maeno T, Shirai K. Optic nerve head circulation  
285 determined by pulse wave analysis is significantly correlated with cardio ankle  
286 vascular index, left ventricular diastolic function, and age. *J Atheroscler Thromb.*  
287 2012;19:999–1005.
- 288 15. Takahashi H, Sugiyama T, Tokushige H, et al. Comparison of CCD-equipped  
289 laser speckle flowgraphy with hydrogen gas clearance method in the  
290 measurement of optic nerve head microcirculation in rabbits. *Exp Eye Res.*  
291 2013;108:10–15.
- 292 16. Shiga Y, Omodaka K, Kunikata H, et al. Waveform analysis of ocular blood flow  
293 and the early detection of normal tension glaucoma. *Invest Ophthalmol Vis Sci.*

- 294 2013;54(12):7699–7706.
- 295 17. Shiga Y, Shimura M, Asano T, et al. The influence of posture change on ocular  
296 blood flow in normal subjects, measured by laser speckle flowgraphy. *Curr Eye*  
297 *Res.* 2013;38:691–698.
- 298 18. Yu DY, Alder VA, Cringle SJ, Su EN, Yu PK. Vasoactivity of intraluminal and  
299 extraluminal agonists in perfused retinal arteries. *Invest Ophthalmol Vis Sci.*  
300 1994;35:4087–4099.
- 301 19. Langham ME, Krieglstein GK. The biphasic intraocular pressure response of  
302 rabbits to epinephrine. *Invest Ophthalmol.* 1976;15:119–127.
- 303 20. Camras CB, Podos SM, Rosenthal JS, Lee PY, Severin CH. Multiple dosing of  
304 prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous  
305 humor dynamics. *Invest Ophthalmol Vis Sci.* 1987;28:463–469.
- 306 21. Becker B, Shin DH. Response to topical epinephrine. A practical prognostic test  
307 in patients with ocular hypertension. *Arch Ophthalmol.* 1976;94:2057–2058.
- 308 22. Funk RH, Wagner W, Rohen JW. The effect of epinephrine on ciliary process  
309 vasculature and IOP studied by intraocular microendoscopy in the albino rabbit.  
310 *Curr Eye Res.* 1992;11:161–173.
- 311 23. Percicot CL, Schnell CR, Debon C, Hariton C. Continuous intraocular pressure  
312 measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in  
313 the rabbit: effects of timolol, dorzolamide, and epinephrine. *J Pharmacol Toxicol*  
314 *Methods.* 1996;36:223–228.
- 315 24. Robinson F, Chen S, Petrig BL, Grunwald JE, Riva CE. The acute effect of  
316 topical epinephrine on macular blood flow in humans. *Invest Ophthalmol Vis Sci.*  
317 1992;33:18–22.

- 318 25. Riva CE, Hero M, Titze P, Petrig B. Autoregulation of human optic nerve head  
319 blood flow in response to acute changes in ocular perfusion pressure. *Graefes*  
320 *Arch Clin Exp Ophthalmol.* 1997;235:618-626.
- 321 26. Pillunat LE, Anderson DR, Knighton RW, Joos KM, Feuer WJ. Autoregulation  
322 of human optic nerve head circulation in response to increased intraocular  
323 pressure. *Exp Eye Res.* 1997;64:737-744.
- 324

325 **Figure Legend**

326

327 Figure 1. Representative changes in ONH blood flow after intravitreal infusion of  
328 epinephrine, as measured by the LSFG-NAVI-OPE™ device.

329

330 Supplementary Material

331

332 Figure S1. Schematic views (A, B) and photos (C, D) of the recently developed device

333 of laser speckle flowgraphy, LSF<sub>G</sub>-NAVI-OPE™ which is a modification of the

334 LSF<sub>G</sub>-NAVI™.

Table 1. Characteristics of each group.

	0.5 mg/500 ml	1.0 mg/500 ml	P value
Age (years)	68.0 ± 9.3	72.6 ± 3.4	0.14 <sup>†</sup>
Male : Female	3 : 8	4 : 7	1.00 <sup>††</sup>
ERM : MH	8 : 3	7 : 4	1.00 <sup>††</sup>
PVD+ : PVD-	9 : 2	8 : 3	1.00 <sup>††</sup>
Combination of phacoemulsification(+:-)	9:2	7:4	0.64 <sup>††</sup>
Systemic medications			
Ca antagonist	6	3	0.39 <sup>††</sup>
ARB	2	3	1.00 <sup>††</sup>
statin	2	3	1.00 <sup>††</sup>
Anti-platelet	1	3	0.59 <sup>††</sup>
Others	ACEI 1 $\alpha$ blocker 1	ACEI 1 $\beta$ blocker 1	1.00 <sup>††</sup>

ERM: epiretinal membrane, MH: macular hole, PVD: posterior vitreous detachment, ARB: Angiotensin receptor blocker, ACEI: Angiotensin converting enzyme inhibitor, <sup>†</sup>: unpaired t-test, <sup>††</sup>: Fisher's exact test

Table 2. Coefficients of variance (%) of MBR measurements (Mean  $\pm$  SD)

	0.5 mg/500 ml		1.0 mg/500 ml	
	Pretreatment	Post- treatment	Pretreatment	Post- treatment
MBR-A	3.3 $\pm$ 1.7	3.1 $\pm$ 1.8	4.0 $\pm$ 1.6	5.8 $\pm$ 3.0
MBR-V	6.2 $\pm$ 4.3	6.0 $\pm$ 3.4	5.7 $\pm$ 3.1	6.9 $\pm$ 4.1
MBR-T	6.5 $\pm$ 4.4	6.5 $\pm$ 4.4	3.8 $\pm$ 2.6	5.7 $\pm$ 3.3

MBR-A: mean of MBRs throughout the ONH, MBR-V: mean of MBRs of vessels of the ONH, MBR-T: mean of MBRs of the ONH tissue.

Table 3. Changes in MBR Values after infusion of epinephrine (Mean  $\pm$  SD)

	0.5 mg/500 ml			1.0 mg/500 ml		
	Pretreatment	Post-treatment	P value	Pretreatment	Post-treatment	P value
MBR-A	17.5 $\pm$ 5.0	16.4 $\pm$ 6.0	0.18	20.5 $\pm$ 7.3	18.4 $\pm$ 6.6	0.008
MBR-V	32.5 $\pm$ 6.9	32.2 $\pm$ 9.9	0.89	36.4 $\pm$ 14.3	34.7 $\pm$ 14.0	0.28
MBR-T	10.2 $\pm$ 2.5	9.0 $\pm$ 2.8	0.003	13.1 $\pm$ 4.3	11.5 $\pm$ 4.0	0.0004



Table 4. Changes in Relative PD, IOP, Blood Pressure,OPP, and Pulse Rate After Infusion of Epinephrine (Mean  $\pm$  SD)



	0.5 mg/500 ml			1.0 mg/500 ml		
	Pretreatment	Post-treatment	P value	Pretreatment	Post-treatment	P value
Relative PD	0.58 $\pm$ 0.09	0.63 $\pm$ 0.08	0.006	0.60 $\pm$ 0.10	0.65 $\pm$ 0.08	0.018
IOP (mmHg)	14.1 $\pm$ 2.3	13.1 $\pm$ 1.9	0.14	14.6 $\pm$ 6.9	13.9 $\pm$ 7.8	0.34
Mean blood pressure (mmHg)	94.9 $\pm$ 12.4	94.2 $\pm$ 13.2	0.29	97.9 $\pm$ 9.4	93.8 $\pm$ 11.3	0.06
OPP(mmHg)	49.2 $\pm$ 8.7	49.7 $\pm$ 9.6	0.53	50.7 $\pm$ 8.1	48.6 $\pm$ 9.5	0.28
Pulse rate (beats/min)	67.3 $\pm$ 11.8	65.7 $\pm$ 7.2	0.53	67.9 $\pm$ 13.1	66.7 $\pm$ 13.7	0.21

# Figure 1

Before treatment

After treatment



0.5 mg/500 ml



MBR-A: 21.8

MBR-A: 21.3

1.0 mg/500 ml



MBR-A: 19.2

MBR-A: 14.7

# Figure S1

